1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,100 | 9,750 | 14:37 | |
| 9,100 | 9,750 | 14:35 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 4 | GlobeNewswire (USA) | ||
| 16.03. | Elicio Therapeutics kündigt "At-the-Market"-Aktienprogramm im Volumen von 100 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 12.03. | Elicio Therapeutics reports FY GAAP EPS of -$2.58 | 2 | Seeking Alpha | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating | 1 | Investing.com | ||
| 09.03. | Rodman & Renshaw startet Coverage für Elicio Therapeutics mit Kaufempfehlung | 3 | Investing.com Deutsch | ||
| 18.02. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 8 | GlobeNewswire (USA) | ||
| 16.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 10 | GlobeNewswire (USA) | ||
| 19.11.25 | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 433 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12 | 2 | Seeking Alpha | ||
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 213 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio meldet starke Immunantworten in Phase-2-Studie zu KRAS-Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 255 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 27.10.25 | Krebstherapie von Elicio zeigt breite Immunantwort bei diversen HLA-Typen | 1 | Investing.com Deutsch | ||
| 27.10.25 | Elicio's cancer therapy shows immune response across diverse HLA types | 2 | Investing.com | ||
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 243 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 17.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial | 239 | GlobeNewswire (Europe) | ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,335 | -6,64 % | NanoRepro: Neue Strategie rund um PHLAS | NanoRepro ist vielen Investoren noch als Anbieter von Corona-Schnelltests bekannt. Doch das Unternehmen hat sich strategisch neu positioniert. Im Podcast "NebenwerteWelt im Gespräch" erläutert CEO Lisa... ► Artikel lesen | |
| OCUGEN | 1,694 | -2,50 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,845 | -0,46 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| COSCIENS BIOPHARMA | 0,795 | 0,00 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,240 | -4,76 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| VAXART | 0,430 | +4,88 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| IBIO | 1,920 | +4,92 % | Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion | ||
| ARBUTUS BIOPHARMA | 3,688 | -0,05 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,320 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,574 | +1,29 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| MANNKIND | 2,088 | -1,51 % | MannKind Announces Settlement of Convertible Senior Notes | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal... ► Artikel lesen | |
| ALDEYRA | 1,893 | +17,47 % | What's Going On With Aldeyra Therapeutics Stock On Thursday? | ||
| TRAWS PHARMA | 2,160 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,434 | +9,39 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +22,34 % bei einem Aktienkurs von 11,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.